INTELLIGENT BIO SOLUTIONS INC.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
Three Months Ended September 30, 2025 and 2024
| Common stock · Treasury stock · Additional paid-in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | capital | deficit | income (loss) | interest | equity | |
| Balance, June 30, 2025 | 7,323,261 | $73,230 | (116) | $(1) | $65,783,916 | $(62,533,065) | $(327,944) | $(182,312) | $2,813,824 |
| Issuance of restricted stock to vendors | 8,164 | 82 | - | - | 11,918 | - | - | - | 12,000 |
| Issuance of common stock, net of issuance costs At Market Offerings | 123,264 | 1,233 | - | - | 212,517 | - | - | - | 213,750 |
| Common stock issued for warrants exercised, net of issuance costs | 1,643,668 | 16,440 | - | - | 3,317,191 | - | - | - | 3,333,631 |
| Foreign currency translation gain | - | - | - | - | - | - | 48,716 | - | 48,716 |
| Net loss | - | - | - | - | - | (2,983,006) | - | (11,986) | (2,994,992) |
| Balance, September 30, 2025 | 9,098,357 | $90,985 | (116) | $(1) | 69,325,542 | $(65,516,071) | $(279,228) | $(194,298) | $3,426,929 |
| Common stock · Treasury stock · Additional paid-in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | capital | deficit | income (loss) | interest | equity | |
| Balance, June 30, 2024 | 3,456,000 | $34,557 | (116) | $(1) | $60,971,740 | $(51,964,332) | $(712,614) | $(146,159) | $8,183,191 |
| Issuance of common stock upon exercise of warrants | 793,930 | 7,939 | - | - | - | - | - | - | 7,939 |
| Stock awards issued to employees | 99,500 | 995 | - | - | 189,050 | - | - | - | 190,045 |
| Issuance of restricted stock to vendors | 11,162 | 112 | - | - | 11,888 | - | - | - | 12,000 |
| Issuance of common stock, net of issuance costs | 17,167 | 172 | - | - | 34,339 | - | - | - | 34,511 |
| Foreign currency translation gain | - | - | - | - | - | - | 216,355 | - | 216,355 |
| Net loss | - | - | - | - | - | (2,685,633) | - | (9,166) | (2,694,799) |
| Balance, September 30, 2024 | 4,377,759 | $43,775 | (116) | $(1) | $61,207,017 | $(54,649,965) | $(496,259) | $(155,325) | $5,949,242 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.